SciELO - Scientific Electronic Library Online

 
vol.49 issue2Recombinant Interferon alfa-2b plus Ribavirin in treatment of chronic hepatitis C author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Cubana de Medicina

On-line version ISSN 1561-302X

Abstract

DORTA GURIDI, Zaily et al. Tolerance to treatment with standard interferon and ribavirin in patients presenting with cirrhosis from hepatitis C. Rev cubana med [online]. 2010, vol.49, n.2, pp. 0-0. ISSN 1561-302X.

In treatment of compensating hepatic cirrhosis of viral etiology the maintained viral response with Interferon and Ribavirin is minor and it is accompanied of a greater frequency of adverse effects in relation to non-cirrhotic patients. However, due to the scarce therapeutical options for this group of patients and the need to retard the appearance of complications, was the reason of present paper. Authors present the results from a group of 36 patients diagnosed with hepatic cirrhosis from HCV in A Child's stage included in multicenter clinical trials, sponsored by the Institute of Gastroenterology; patients received a therapeutical scheme of Interferon alfa-2b plus Ribavirin during 48 weeks assessing their tolerance by clinical and hematologic adverse events. Results demonstrate that this treatment alternative is safe and well-tolerated.

Keywords : Treatment; hepatic cirrhosis by hepatitis C virus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License